Get the Stockscreener App
3.9652
2.19%
0.0852
Aquestive Therapeutics Inc stock is traded at $3.9652, with a volume of 929.57K.
It is up +2.19% in the last 24 hours and down -6.26% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$3.88
Open:
$3.85
24h Volume:
929.57K
Relative Volume:
0.68
Market Cap:
$395.90M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-10.89
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
-3.53%
1M Performance:
-6.26%
6M Performance:
+31.73%
1Y Performance:
-14.73%
1-Day Range:
$3.82
$3.9901
1-Week Range:
$3.805
$4.255
52-Week Range:
$2.12
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.97 | 416.84M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
156.57 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.32 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.835 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.50 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
310.57 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive's Anaphylm to be reviewed by Health Canada - MSN
Chart based exit strategy for Aquestive Therapeutics Inc.July 2025 Short Interest & AI Powered Buy and Sell Recommendations - Newser
Analyzing recovery setups for Aquestive Therapeutics Inc. investorsQuarterly Market Summary & Daily Chart Pattern Signal Reports - Newser
Order flow analysis tools used on Aquestive Therapeutics Inc.Weekly Market Summary & Real-Time Price Movement Reports - Newser
Aquestive Therapeutics Inc. stock retracement – recovery analysisVolume Spike & Weekly Watchlist for Hot Stocks - Newser
Analyzing net buyer seller activity in Aquestive Therapeutics Inc.July 2025 Short Interest & Weekly Breakout Opportunity Watchlist - Newser
Unlocking Growth in Specialty Pharma: RTW Biotech's Strategic $75M Investment in Aquestive's Anaphylm - AInvest
Aquestive outlines patient-first Anaphylm launch strategy and maintains 2025 revenue guidance amid FDA review progress - MSN
$160m War Chest Readied For Aquestive’s Oral Epinephrine Film Launch - insights.citeline.com
Aquestive signs $75m agreement for launch of Anaphylm - Yahoo Finance
Evaluating Aquestive Therapeutics Inc. with trendline analysisJuly 2025 Trends & Weekly Return Optimization Alerts - Newser
Why Aquestive Therapeutics Inc. is moving today2025 Trading Recap & Fast Gaining Stock Strategy Reports - Newser
Technical analysis overview for Aquestive Therapeutics Inc. stockWeekly Market Report & Technical Pattern Based Signals - Newser
Earnings visualization tools for Aquestive Therapeutics Inc.CEO Change & Weekly Watchlist for Hot Stocks - Newser
Can Aquestive Therapeutics Inc. ride the EV waveQuarterly Performance Summary & Long-Term Safe Investment Ideas - thegnnews.com
Real time breakdown of Aquestive Therapeutics Inc. stock performanceQuarterly Investment Review & Free Expert Approved Momentum Trade Ideas - Newser
Understanding Aquestive Therapeutics Inc.’s price movementMarket Sentiment Report & Short-Term High Return Strategies - Newser
AQST FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Will Aquestive Therapeutics Inc. price bounce be sustainablePortfolio Growth Summary & High Accuracy Swing Entry Alerts - Newser
Aquestive Therapeutics Inc. Forms Bullish Flag — Upside AheadMarket Sentiment Report & Accurate Trade Setup Notifications - metal.it
Is Aquestive Therapeutics Inc. stock entering bullish territoryEarnings Recap Summary & Reliable Price Action Trade Plans - Newser
Why Aquestive Therapeutics Inc. stock attracts strong analyst attention2025 Market Outlook & AI Forecasted Entry/Exit Points - Newser
Aquestive Therapeutics Announces $85M Stock Offering - MSN
How is Aquestive Therapeutics Inc. managing supply chain issues2025 Earnings Surprises & Free Growth Oriented Trading Recommendations - thegnnews.com
Pattern recognition hints at Aquestive Therapeutics Inc. upsideVolume Spike & Comprehensive Market Scan Insights - Newser
Leerink Partnrs Has Positive Forecast for AQST Q3 Earnings - Defense World
Aquestive Therapeutics rises after pricing $85M stock offering - MSN
Aquestive Therapeutics announces pricing of $85 million underwritten offering of shares - ROI-NJ
Aquestive Therapeutics: Advancing Anaphylm and Strategic Preparations Support Buy Rating - TipRanks
Published on: 2025-08-15 06:30:05 - newsyoung.net
Aquestive Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st
Aquestive Therapeutics rises after $85 million stock sale - TradingView
Aquestive Therapeutics Announces $75M Strategic Funding - citybiz
Aquestive’s $85M offering and royalty deal; Basilea gets rights to UTI drug candidate - Endpoints News
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Aquestive Therapeutics stock rises after securing $75 million funding deal By Investing.com - Investing.com Australia
Aquestive Therapeutics stock rises after securing $75 million funding deal - Investing.com
Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail - Stocktwits
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Have Been Cutting Their Estimates - 富途牛牛
Aquestive Therapeutics Prices $85 Million Common Stock Offering - MarketScreener
Aquestive Therapeutics Secures $75M Funding for Anaphylm - TipRanks
Aquestive Therapeutics prices $85 million public offering By Investing.com - Investing.com Canada
Aquestive Therapeutics prices $85 million public offering - Investing.com India
Aquestive Therapeutics Secures $75 Million Funding Agreement with RTW - MarketScreener
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock - The Manila Times
Aquestive Therapeutics announces $75m strategic funding agreement with RTW - MarketScreener
Aquestive Secures $85M Backing to Launch Novel Sublingual Film for Severe Allergic Reactions - Stock Titan
First-Ever Oral Emergency Allergy Treatment Gets $75M Boost from RTW Investment - Stock Titan
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2025 Earnings Call Transcript - Insider Monkey
Is it time to cut losses on Aquestive Therapeutics Inc.Weekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):